当前位置:
X-MOL 学术
›
Eur. Respir. J.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Is tezepelumab more than just an anti-eosinophil drug?
European Respiratory Journal ( IF 16.6 ) Pub Date : 2021-12-31 , DOI: 10.1183/13993003.01700-2021 Adil Adatia 1, 2 , Mustafaa Wahab 1 , Imran Satia 2, 3
中文翻译:
tezepelumab 不仅仅是一种抗嗜酸性粒细胞药物吗?
更新日期:2021-12-31
European Respiratory Journal ( IF 16.6 ) Pub Date : 2021-12-31 , DOI: 10.1183/13993003.01700-2021 Adil Adatia 1, 2 , Mustafaa Wahab 1 , Imran Satia 2, 3
Affiliation
Tezepelumab significantly reduces airway eosinophilia, which is the most likely mechanism by which it reduces the risk of asthma exacerbation in patients with moderate–severe asthma, but has little effect on airway hyperresponsiveness to mannitol https://bit.ly/3xnt5sS
中文翻译:
tezepelumab 不仅仅是一种抗嗜酸性粒细胞药物吗?
Tezepelumab 显着降低气道嗜酸性粒细胞增多,这是降低中重度哮喘患者哮喘恶化风险的最可能机制,但对甘露醇的气道高反应性几乎没有影响https://bit.ly/3xnt5sS